SLC5A2 and cancer: On the other hand, a meta-analysis of randomized clinical trials revealed a clear association between SGLT2 inhibitors and a notable reduction in the overall risk of cancer compared to a placebo, particularly highlighting the effectiveness of dapagliflozin and ertugliflozin [109].